Equity Overview
Price & Market Data
Price: $3.53
Daily Change: +$0.04 / 1.13%
Daily Range: $3.44 - $3.55
Market Cap: $296,105,088
Daily Volume: 305,799
Performance Metrics
1 Week: -4.95%
1 Month: -7.98%
3 Months: 27.68%
6 Months: 10.90%
1 Year: 5.49%
YTD: 3.28%
Company Details
Employees: 56
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.